Frog Investigation !

Quote












Dendreon ($DNDN) is under investigation by the Securities and Exchange Commission. As Dow Jones reports, the company disclosed the SEC probe in its quarterly filing, along with information about shareholder lawsuits that accuse the company of misleading investors about its prostate cancer therapy Provenge.

The lawsuits, now consolidated in federal court in Washington, claim that Dendreon and some executives and former executives made false*or misleading public statements about the Provenge launch. Some allege that officials misappropriated company information and engaged in insider trading, the news service reports.

In the SEC filing, Dow Jones says, Dendreon says the lawsuits are without merit and that it intends to fight them. The SEC wouldn't comment.

The much-anticipated Provenge was approved by the FDA in April 2010. Early uptake of the drug proceeded slowly, but the company reminded investors that production limitations--and the drug's personalized nature--put natural limitations on the launch. As production expanded and more doctors gained familiarity with the drug, that was expected to change.

As Dow Jones reports, Dendreon revealed in August last year that doctors' adoption of the drug had slowed because of reimbursement issues. The company slashed its revenue forecast and the stock plummeted. Since then, the company has hired a new CEO, and it says Provenge is gaining.
 






Hopefully Gold will go to jail for putting his financial interests before patients, employees, the company, and shareholders.

Johnson has the skills to turn this company around. Provenge is a good product. Johnson was able to completely turn around Imclone after Sam Waksal went to jail after the SEC investigation showing he violated insider trading laws. Johnson should be able to do the same for Dendreon.
 






This is probably something that can't be turned around. They sell a much different kind of product. This product is so unique and has too many inefficiencies to not be under a big pharma umbrella that has scale. Additionally Johnson just doesn't seem fully engaged. He pretty much works out of NJ and his earnings calls seem to indicate someone with not much energy or interest.

Everyone has varying opinions but the thing we all seem to agree on is that Gold should go to prison. This is really a sleazy horrible man. He now brings his act to the new company he is on the board of. How long will that last?
 






Top Bottom
Back
Quote